<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126317</url>
  </required_header>
  <id_info>
    <org_study_id>VGFTe (HD)-AMD-1905</org_study_id>
    <nct_id>NCT04126317</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration</brief_title>
  <acronym>CANDELA</acronym>
  <official_title>A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are to determine the safety of high-dose aflibercept
      (hereafter referred to as HD) and to determine if HD provides greater intraocular
      pharmacodynamic (PD) effect and/or longer duration of action compared to intravitreal
      aflibercept injection (hereafter referred to as IAI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 27, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-masked: The patients, visual acuity examiners, imaging technicians and reading center will be masked to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients without retinal fluid in the center subfield</measure>
    <time_frame>At week 20</time_frame>
    <description>Presence of retinal fluid is assessed by spectral domain optical coherence tomography (SD-OCT)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neovascular (Wet) Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>intravitreal aflibercept injection (IAI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve patients with neovascular &quot;wet&quot; age-related macular degeneration (nAMD) randomized in a 1:1 ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose aflibercept (HD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve patients with nAMD randomized in a 1:1 ratio</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept</intervention_name>
    <description>Intravitreally (IVT) administered as a liquid formulation in a vial</description>
    <arm_group_label>intravitreal aflibercept injection (IAI)</arm_group_label>
    <other_name>EYLEA®</other_name>
    <other_name>BAY86-5321</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose aflibercept</intervention_name>
    <description>Intravitreally (IVT) administered as a liquid formulation in a vial</description>
    <arm_group_label>High-dose aflibercept (HD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Men or women ≥50 years of age with active subfoveal choroidal neovascularization (CNV)
             secondary to nAMD

          -  Best Corrected Visual Acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS)
             letter score of 78 to 24 (Snellen equivalent of 20/32 to 20/320) in the study eye

        Key Exclusion Criteria:

          -  Evidence of CNV due to any cause other than nAMD in either eye

          -  Evidence of diabetic macular edema (DME) or diabetic retinopathy (defined as more than
             1 microaneurysm) in either eye in diabetic patients

          -  Prior use of IVT anti-VEGF agents (aflibercept, ranibizumab, bevacizumab,
             brolucizumab, pegaptanib sodium) in the study eye

          -  Prior IVT investigational agents in either eye (eg, anti-ang-2/anti-VEGF bispecific
             monoclonal antibodies, gene therapy)

          -  Previous use of intraocular or periocular corticosteroids within 120 days of screening
             or treatment with an IVT steroid implant at any time in the study eye

          -  History of vitreoretinal surgery (including scleral buckling) in the study eye

          -  Any other intraocular surgery within 12 weeks (84 days) before the screening visit

          -  History of corneal transplant or corneal dystrophy in study eye

        NOTE: Other protocol defined inclusion/exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

